Showing 108 of 108on this page. Filters & sort apply to loaded results; URL updates for sharing.108 of 108 on this page
CAB Portfolio - BioAtla
BioAtla gets FDA nod to start trials of BA3361, a CAB targeting Nectin ...
Conditionally Active Biologics™ (CAB) - BioAtla
BioAtla August 2025 slides: promising clinical data amid financial ...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for ...
BioAtla Investor Presentation Deck | Slidebook.io
BioAtla IPO Presentation Deck | Slidebook.io
BioAtla (BCAB.O) Plummets 15% Intraday—What’s Behind the Sudden Drop?
BioAtla Virtual R&D Day: BA3071 CAB-CTLA-4 Phase 1 Data Review in ...
BioAtla | | The Pharmaletter
BioAtla posts 2025 loss, starts strategic review | BCAB 8-K Filing
BioAtla Raises $72.5 Million In Series D Financing to Advance CAB-AXL ...
BioAtla (BCAB) sets $40M SPV to fund Phase 3 Oz-V OPSCC trial | BCAB ...
IPO BioAtla Inc (BCAB)
BioAtla (BCAB|$17.7M) - 2024 Q4 & Full Year Earnings Analysis - YouTube
BioAtla pursues strategic review, cancer pipeline focus | BCAB Annual ...
BioAtla - BioAtla
BioAtla and GATC Health Announce $40M SPV Transaction to Advance ...
BioAtla (BCAB) Q3 2024 Earnings Results & Call Transcript
BioAtla Inc. (BCAB) | IPO 2020
BCAB Stock Price, News & Analysis | Bioatla
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M ...
BioAtla 將在 2025 年財報發佈後啟動資產變現
BioAtla Axes 70% of Staff, Exploring Strategic Options Amidst Industry ...
BioAtla & GATC Health: Oz-V Phase III Oncology Trial
BioAtla Reports $69.8 Million Net Loss in 2024 with Promising Clinical ...
Publications - BioAtla
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC ...
BioAtla Presents Evalstotug at SMR
Bioatla - AnnualReports.com
BioAtla 的pH条件性激活 ROR2-ADC - 知乎
BioAtla plans 1-for-50 reverse split to support Nasdaq | BCAB SEC ...
BioAtla (BCAB.O) Plunges 15%—What’s Behind the Sharp Move?
BioAtla to Complete Merger with BA Merger Sub on April 6
Bioatla 2024 Q3 Earnings Net Loss Widens to $15.8M Amid Strategic Progress
国外Biotech公司ADC产品技术特色医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
国外Biotech公司ADC产品技术特色
CAB-AXL-ADC新药早期临床结果积极，BioAtla盘前飙升47%医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Bioatla宣布CAB-AXL-ADC產品IND申請獲得FDA批准丨醫麥優企秀 - 每日頭條
BioAtla条件性pH激活抗 EpCAM x CD3 双特异性抗体设计 - 知乎
BioAtla's Innovative Cancer Biologics | PDF | Medicine | Causes Of Death
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Increase in Short Interest ...
PESTEL Analysis of BioAtla, Inc. (BCAB)
BioAtla_百度百科
Ocuphire Pharma Investor Day Presentation Deck | Slidebook.io
Buy BioAtla, Inc Stock – BCAB Stock Quote Today & Investment Insights ...
BCAB Q2 2025 Earnings Report on 8/7/2025
开发创新抗癌疗法！BioAtla完成7250万美元D轮融资，百济神州已与其达成合作 - 知乎
BCAB Stock | Bioatla, Inc. Price, Quote, News & Analysis - TipRanks.com
Exploiting the Tumor Microenvironment – Threshold, Bioatla, Pfizer ...
BCAB Q4 2024 Earnings Report on 3/27/2025
XBRL Viewer
ADC药物：CAB-ROR2-ADC报IND！来自凯博斯，抗体在肿瘤微环境下被激活！_摩熵医药
BioAtla, Inc. | San Diego CA
上海旭珩资产管理有限公司
BCAB Q4 2023 Earnings Report on 3/26/2024
国内首家！BioAtla申报靶向ROR2的ADC - 知乎
BioAtla, Inc. (BCAB) Stock Price, News, Quote & History - Yahoo Finance
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) | Seeking Alpha
【BCAB】Bioatla カタリストとロードマップ | Zoomy (ズーミー)
BioAtla’s AACR 2025 Breakthroughs: A New Frontier in Precision Oncology
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript - Insider ...
Melanoma investor presentations and pitch decks | Slidebook
Weekly digest 20 to 26 july 2024 - Optimal Dose
BCAB Q3 2024 Earnings Report on 11/7/2024
%201.jpg)
.jpg)
